Skip to content
20-F

Annual Report (Foreign)

PURPLE BIOTECH LTD. PPBT

0001213900-26-031365

← back to feed
Filed
Mar 19, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2025 · Dec 31, 2025 960.11M sh
Shares Outstanding FY 2025 · Dec 31, 2025 1.86B sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$5.66M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$14.37M
Operating Cash Flow FY 2025 · Dec 31, 2023 −$19.93M
Cash And Equivalents FY 2025 · Dec 31, 2025 $8.72M
Cash And Equivalents FY 2025 · Dec 31, 2024 $7.4M
Cash And Equivalents FY 2025 · Dec 31, 2023 $14.49M
Cash And Equivalents FY 2025 · Dec 31, 2022 $15.03M
Stockholders Equity FY 2025 · Dec 31, 2025 $9.66M
Stockholders Equity FY 2025 · Dec 31, 2024 $32.91M
Stockholders Equity FY 2025 · Dec 31, 2023 $34.3M
Stockholders Equity FY 2025 · Dec 31, 2022 $47.1M
Current Liabilities FY 2025 · Dec 31, 2025 $7.75M
Current Liabilities FY 2025 · Dec 31, 2024 $3.99M
Current Assets FY 2025 · Dec 31, 2025 $9.87M
Current Assets FY 2025 · Dec 31, 2024 $8.91M
Total Assets FY 2025 · Dec 31, 2025 $17.57M
Total Assets FY 2025 · Dec 31, 2024 $37.04M
Eps Diluted FY 2025 · Dec 31, 2025 $0.03
Eps Basic FY 2025 · Dec 31, 2025 $0.03
Rd Expense FY 2025 · Dec 31, 2025 $3.73M
Rd Expense FY 2025 · Dec 31, 2024 $7.62M
Rd Expense FY 2025 · Dec 31, 2023 $17.03M